Semaglutide shortage ends as FDA sets deadline for compounders
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Domino's Pizza earnings on tap; Zoom, Hims and Hers after the close
Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...
Stocktwits on MSN5 小时
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop ...
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...
pharmaphorum2 小时
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
HIMS财报前瞻：涨幅超200%后，估值现已过高
但当 HIMS 在 12 月 6 日达到其最后一个波动高点时（使用收盘价），该股的收盘价为 34.23 美元，仅比其 50 天移动平均线 23.29 美元高出 47%。同样，其 2024 年 6 月 18 日的波动高点比当时的 50 天移动平均线高出 ...
财联社 on MSN2 天
美FDA宣布司美格鲁肽不再短缺，为何诺和诺德股价大涨？
财联社2月22日讯（编辑 赵昊）当地时间周五（2月21日），美国食品和药物管理局（FDA）官网显示，诺和诺德公司报告称司美格鲁肽注射液的短缺和停产情况已经解决。 FDA表格显示，用于治疗2型糖尿病的“Ozempic”（诺和泰）和用于体重管理的“Wegovy”（诺和盈）已经不再供不应求，这类热门药物的短缺情况最早始于2022年8月23日。